Wiener klinische Wochenschrift

, Volume 125, Issue 7–8, pp 225–226 | Cite as

Agomelatine-induced hepatotoxicity

letter to the editor

References

  1. 1.
    Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today. 2009;45:599–608.PubMedCrossRefGoogle Scholar
  2. 2.
    Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med. 2002;40:718–24.PubMedGoogle Scholar
  6. 6.
    Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 3. Reference procedure for the measurement of catalytic concentration of lactate dehydrogenase. Clin Chem Lab Med. 2002;40:631–4.PubMedGoogle Scholar
  7. 7.
    Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30:135–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol. 2006;21 Suppl 1:S31–5.Google Scholar
  9. 9.
    De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Rep Psychiatry. 2012;2012:642752.PubMedGoogle Scholar
  10. 10.
    Müller H, Seifert F, Maler JM, et al. Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients. Singapore Med J. 2012;53:e228–30.Google Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  1. 1.Psychiatric Hospital OrmozOrmozSlovenia

Personalised recommendations